Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Carnival ADR Representing 1 Ord Shs CUK

Alternate Symbol(s):  CUKPF

Carnival PLC is a global cruise company. The Company’s segments include North America and Australia (NAA) cruise operations, Europe and Asia (EA) cruise operations, Cruise Support, and Tour and Other. NAA cruise operations include Carnival Cruise Line, Princess Cruises, Holland America Line, P&O Cruises (Australia), and Seabourn. The EA segment includes Costa Cruises (Costa), AIDA Cruises (AIDA), P&O Cruises (UK) and Cunard. Cruise Support segment includes its portfolio of port destinations and other services, all of which are operated for the benefit of its cruise brands. Tour and Other segment represent the hotel and transportation operations of Holland America Princess Alaska Tours and other operations. Holland America Princess Alaska Tours is a tour company in Alaska and the Canadian Yukon, which complements its Alaska cruise operations. The Company’s cruise line brands offer a range of vacation options for guests with a variety of leisure-time activities.


NYSE:CUK - Post by User

Post by NicoleYheon Feb 05, 2022 1:42am
178 Views
Post# 34400450

FSD Pharma Inc: Lucid MS Video

FSD Pharma Inc: Lucid MS VideoFSD Pharma is pleased to share pre-clinical data demonstrating the effectiveness of its lead drug candidate, Lucid-MS, in treating Multiple Sclerosis. The unique potential therapeutic value of Lucid-MS is an industry-first and we want to share the visual evidence of functional recovery of pre-clinical subjects in this video!
<< Previous
Bullboard Posts
Next >>